Skip to main content
Evidence Snapshot

Liver

CHEMBL613642 TISSUE Rattus norvegicus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613642
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Liver as ChEMBL target CHEMBL613642. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Liver
TISSUE · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL613642
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Liver matters

As of 2026-09-13

Liver is reviewed as Liver; the current evidence base includes 15 approved drugs, 2804 compounds, and 1330 assays, with lead potency reaching pChEMBL 7.8.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 15 approved drugs, 2804 compounds, and 1330 assays for this target. The dominant activity type is IC50. CHEMBL472 is the current potency anchor at pChEMBL 7.8.

Use CHEMBL472 as the tractability anchor when discussing potency (pChEMBL 7.8).

Activity source · ChEMBL 36 via Core Engine
15 approved pChEMBL 7.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Liver matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2804
Total Compounds
1330
Total Assays
15
Approved Drugs
IC50: 254.0, EC50: 12.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL472
 7.8 IC50 Approved
No preferred name
CHEMBL1336
 7.7 IC50 Approved
No preferred name
CHEMBL1200624
 7.7 IC50 Approved
No preferred name
CHEMBL623
 7.5 IC50 Approved
No preferred name
CHEMBL547
 7.3 IC50 Approved

Approved Drugs

Structure Compound First Approval
SORAFENIB
CHEMBL1336
 2005
TELMISARTAN
CHEMBL1017
 1998
TROGLITAZONE
CHEMBL408
 1997
ZAFIRLUKAST
CHEMBL603
 1996
BICALUTAMIDE
CHEMBL409
 1995
NEFAZODONE
CHEMBL623
 1994
FLUTAMIDE
CHEMBL806
 1989
GLYBURIDE
CHEMBL472
 1984
ISOTRETINOIN
CHEMBL547
 1982
KETOCONAZOLE
CHEMBL157101
 1981
DANAZOL
CHEMBL1479
 1976
ERYTHROMYCIN ESTOLATE
CHEMBL2218877
 1967
ETHYNODIOL DIACETATE
CHEMBL1200624
 1966
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL613642